학술논문
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks
Document Type
Article
Author
Source
In The Journal of Allergy and Clinical Immunology February 2024 153(2):479-486
Subject
Language
ISSN
0091-6749